
Roche’s ‘Operational Excellence’ programme will see it cut 6% of its global workforce over the next two years. The initiative …
Roche has admitted it does not know when phase III trials of the investigational type II diabetes drug taspoglutide will …
Phase III results for Roche’s once-weekly injectable drug taspoglutide have shown a positive effect on reducing blood glucose compared with …

